{"prompt": "['(for Type I diabetes mellitus) as', 'appropriate.', 'Rule-out secondary endocrinopathies', '(i.e. hypopituitarism. / hypophysitis)', 'Grade 3 or Grade 4', 'Withhold avelumab therapy', 'Resume avelumab once', 'endocrinopathies', 'Consider hospitalization', 'symptoms and/or laboratory', '(hypothyroidism,', 'Endocrinology consult', 'tests improve to Grade < 1', 'hyperthyroidism, adrenal', '(with or without hormone', 'insufficiency, type I diabetes', 'replacement/suppression).', 'Start thyroid hormone replacement', 'mellitus)', 'therapy (for hypothyroidism).', 'anti-thyroid treatment (for', 'Continue hormone', 'hyperthyroidism), corticosteroids', 'replacement/suppression and', '(for adrenal insufficiency) or insulin', 'monitoring of endocrine', '(for type I diabetes mellitus) as', 'function as appropriate.', 'appropriate.', 'Rule-out secondary endocrinopathies', '(i.e. hypopituitarism / hypophysitis)', 'Hypopituitarism/Hypophysitis', 'If secondary thyroid and/or adrenal', 'Resume avelumab once', '(secondary endocrinopathies)', 'insufficiency is confirmed (i.e.', 'symptoms and hormone tests', 'subnormal serum FT4 with', 'improve to Grade < 1 (with', 'inappropriately low TSH and/or low', 'or without hormone', 'serum cortisol with inappropriately', 'replacement).', 'low ACTH) :', 'Refer to endocrinologist for', 'In addition, for hypophysitis', 'dynamic testing as indicated and', 'with abnormal MRI, resume', 'measurement of other hormones', 'avelumab only once', '(FSH, LH, GH/IGF-1, PRL,', 'shrinkage of the pituitary', 'testosterone in men, estrogens in', 'gland on MRI/CT scan is', 'women)', 'documented.', 'Hormone', 'replacement/suppressive therapy', 'Continue hormone', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '35']['as appropriate', 'replacement/suppression', 'Perform pituitary MRI and visual', 'therapy as appropriate.', 'field examination as indicated', 'If hypophysitis confirmed:', 'Continue avelumab if mild', 'symptoms with normal MRI.', 'Repeat the MRI in 1 month', 'Withhold avelumab if moderate,', 'severe or life-threatening', 'symptoms of hypophysitis and/or', 'abnormal MRI. Consider', 'hospitalization. Initiate', 'corticosteroids (1 to 2 mg/kg/day', 'prednisone or equivalent)', 'followed by corticosteroids taper', 'during at least 1 month.', 'Add prophylactic antibiotics for', 'opportunistic infections.', 'Other irAEs (not described above)', 'Grade of other irAEs', 'Initial Management', 'Follow-up Management', '(NCI-CTCAE v4)', 'Grade 2 or Grade 3 clinical', 'Withhold avelumab therapy pending', 'If irAE is ruled out, manage', 'signs or symptoms suggestive', 'clinical investigation', 'as appropriate according to', 'of a potential irAE', 'the diagnosis and consider', 're-starting avelumab therapy', 'If irAE is confirmed, treat as', 'Grade 2 or 3 irAE.', 'Grade 2 irAE or first', 'Withhold avelumab therapy', 'If improves to Grade <1 1:', 'occurrence of Grade 3 irAE', '1.0 to 2.0 mg/kg/day prednisone or', 'Taper steroids over at least 1', 'equivalent', 'month and resume avelumab', 'Add prophylactic antibiotics for', 'therapy following steroids', 'opportunistic infections', 'taper.', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '36']['Specialty consult as appropriate', 'Recurrence of same Grade 3', 'Permanently discontinue avelumab', 'If improves to Grade < 1:', 'irAEs', 'therapy', 'Taper steroids over at least 1', '1.0 to 2.0 mg/kg/day', 'month.', 'prednisone or equivalent', 'Add prophylactic antibiotics for', 'opportunistic infections', 'Specialty consult as appropriate', 'Grade 4', 'Permanently discontinue avelumab', 'If improves to Grade V 1:', 'therapy', 'Taper steroids over at least 1', '1.0 to 2.0 mg/kg/day', 'month', 'prednisone or equivalent and/or', 'other immunosuppressant as needed', 'Add prophylactic antibiotics for', 'opportunistic infections', 'Specialty consult.', 'Requirement for 10 mg per', 'Permanently discontinue avelumab', 'day or greater prednisone or', 'therapy', 'equivalent for more than 12', 'Specialty consult', 'weeks for reasons other than', 'hormonal replacement for', 'adrenal insufficiency', 'Persistent Grade 2 or 3 irAE', 'lasting 12 weeks or longer', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '37']\n\n###\n\n", "completion": "END"}